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ABSTRACT
The spliceosome is a large molecular machine that
serves to remove the intervening sequences that
are present in most eukaryotic pre-mRNAs. At its
core are five small nuclear ribonucleoprotein com-
plexes, the U1, U2, U4, U5 and U6 snRNPs, which
undergo dynamic rearrangements during splicing.
Their reutilization for subsequent rounds of splic-
ing requires reversion to their original configura-
tions, but little is known about this process. Here, we
show that ZK863.4/USIP-1 (U Six snRNA-Interacting
Protein-1) is a ribonucleotidyl transferase that pro-
motes accumulation of the Caenorhabditis elegans
U6 snRNA. Endogenous USIP-1–U6 snRNA com-
plexes lack the Lsm proteins that constitute the
protein core of the U6 snRNP, but contain the U6
snRNP recycling factor SART3/B0035.12. Further-
more, co-immunoprecipitation experiments suggest
that SART3 but not USIP-1 occurs also in a sepa-
rate complex containing both the U4 and U6 snRNPs.
Based on this evidence, genetic interaction between
usip-1 and sart-3, and the apparent dissociation of
Lsm proteins from the U6 snRNA during spliceo-
some activation, we propose that USIP-1 functions
upstream of SART3 to promote U6 snRNA recycling.
INTRODUCTION
A set of five U snRNAs, U1, U2, U4, U5 and U6 snRNAs,
is central to most pre-mRNA splicing events in eukaryotes
(1). These RNAs occur in ribonucleoprotein (RNP) com-
plexes that comprise a core set of seven Sm proteins in the
case of U1, U2, U4 and U5, and seven Sm-like (Lsm) pro-
teins in the case of U6 (2). The splicing process involves
extensive changes of U snRNP structure and composition
(1,3). For example, extensive base-pairing with U4 main-
tains U6 in an inactive conformation during its recruitment
as a U4/U6.U5 tri-snRNP to the pre-spliceosome, which
contains pre-mRNA bound to U1 and U2 snRNPs. Major
rearrangements of U6 then lead to disruption of the U4–
U6 snRNA base-pairing in favor of U6–U2 snRNA base-
pairing, resulting in release ofU4 snRNA (3).Moreover,U6
binding to the 5′ splice site displaces the U1 snRNA leading
to its release from the spliceosome (3).
Following execution of the splicing step, U2, U5 and U6
snRNPs and the resected intron lariat are released and fur-
ther disassembled throughmechanisms that are not well un-
derstood (1). Reuse of the snRNPs for further rounds of
splicing thus requires regeneration of their distinct, initial
conformations and interactions. For theU6 snRNP, this ‘re-
cycling’ includes the reformation of a U4/U6 snRNP. Ge-
netic studies in yeast implicated the RNA-binding protein
Prp24p in this process (4,5) and subsequent studies have
shown that Prp24p promotes annealing of the U4 and U6
snRNAs by structurally rearranging the U6 snRNA (6,7).
For the related human protein, SART3/p110/TIP110, a
similar function as a U4/U6 snRNP annealing factor
has been described (8,9). In addition, however, SART3
(squamous-cell carcinoma antigen recognized by T cells-3
(10)) has been implicated in transcriptional activation (11)
and repression (12), deubiquitination (13,14), and small
RNA silencing pathways (15).
U6 stands out amongU snRNAs, and non-codingRNAs
more generally, by virtue of its high degree of conservation
(16), exhibiting 75% sequence identity between yeast and
human and 91% between Caenorhabditis elegans and hu-
man. This may reflect its central role in the splicing pro-
cess where it is thought to contribute, together with the
U2 snRNA, to the active site of the spliceosome (17). U6
snRNA is also unique among U snRNAs in that it is tran-
scribed by RNA polymerase III (Pol III) rather than Pol II
(18). Because Pol III transcription is terminated by a stretch
of four to six consecutive deoxythimidines (19), the 3′ end
of U6 thus consists of a short stretch of uridines. For mam-
malian U6, the precise number of Us appears to be variable,
ranging from 0 to 12 U residues (20–22), possibly reflecting
the antagonistic activities of exonucleolytic shortening and
non-templated extension.
The uridine tail at the 3′ end of the nascent Pol III tran-
script is bound by the La protein, which protects it from ex-
onucleolytic degradation (23). In the case ofU6 snRNA, the
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U-tail is subsequently bound by Lsm proteins in both yeast
and mammals, replacing the La protein (24–26). Lsm pro-
teins in turn stabilizeU6 snRNA (27) and enhance the bind-
ing of Prp24p/SART3 to U6 snRNA to facilitate U4/U6
snRNA annealing (25,28,29). Hence, the uridine tail at the
3′ end of U6 snRNA is pivotal for its stability and recycling.
Here, we report the role of a previously uncharacter-
ized protein, ZK863.4/USIP-1, in U6 snRNA metabolism.
USIP-1 is a ribonucleotidyl transferase that binds U6
snRNA and promotes its accumulation. In addition, USIP-
1 interacts genetically and physically with SART3, but, un-
like SART3, does not bind to the U4/U6 di-snRNP. Hence,
these data suggest that USIP-1 functions to promote U6
snRNA recycling with, and upstream of, SART3.
MATERIALS AND METHODS
Strains
Strains were cultured using standard methods on OP50-
seeded NGM plates (30). The Bristol N2 strain was
used as wild-type. Mutant and transgenic strains gen-
erated for this study are listed in Supplementary Table
S3. Most lines were obtained by Mos1-mediated Single-
Copy transgene Insertion as previously described (MosSCI;
(31,32)). All strains have been backcrossed two times,
unless indicated otherwise. usip-1(tm1897) animals were
obtained from Dr Shohei Mitani and backcrossed two
times. The resulting strain was called HW1251. Strains
HW1340 and HW1342 contain extrachromosomal arrays
of GFP/3xFLAG-tagged fosmids which were obtained
from (33).
Cloning
The sart-3 and usip-1 gene were amplified from genomic C.
elegans DNA by PfuUltra II Fusion HS DNA Polymerase
(Agilent Technologies, SantaClara, CA,USA) according to
the supplier’s protocol using specific primers (Supplemen-
tary Table S4). Point mutations D183A and D185A were
introduced to usip-1 (amplified from genomicDNA) by site-
directed mutagenesis using PfuUltra II Fusion HS DNA
Polymerase according to (34) with specific primers (Supple-
mentary Table S4). D183A and D185A were introduced to
the cDNA of usip-1 for recombinant protein expression us-
ingGibsonAssembly according to (35)with specific primers
(Supplementary Table S4).
RNAi
The RNAi clone against sart-3 was obtained from (36).
RNAi was carried out by feeding worms with HT115 bac-
teria expressing dsRNA of sart-3 or an insertless plasmid
(L4440) as negative control according to (37).
Single-copy transgene insertion
DNA fragments were inserted into pCFJ210 (for chromo-
some I), pCFJ150 (for chromosome II) or pCFJ201 (for
chromosome IV) vectors by Multisite Gateway Technol-
ogy (Life Technologies, Carlsbad, CA, USA) according to
the supplier’s protocol and as detailed in Supplementary
Table S3. Mos1-mediated Single-Copy transgene Insertion
(MosSCI) was performed according to previous reports
(31,32). Successful insertion of transgenes was verified by
polymerase chain reaction (PCR).
Fluorescence-based worm sorting
As a consequence of the lethal phenotype of worms
homozygous for the xe3 allele (xe3/xe3), these worms
were maintained as heterozygotes (xe3/+) utilizing the
nT1[qls51] balancer containing a fluorescent marker (pha-
ryngeal GFP) (strain HW1337; Supplementary Table
S3). This allows differentiation between xe3/xe3 worms,
which lack pharyngeal GFP, and xe3/+ and +/+ worms,
which have pharyngeal GFP. Homogenous populations
of xe3/xe3 worms were obtained by sorting out GFP-
containing worms from a mixed population on a CO-
PAS BIOSORT device (Union Biometrica, Holliston, MA,
USA).
Antibodies and western blotting
Polyclonal, affinity purified anti-SART3 was generated by
SDIX (Newark, DE, USA) using DNA immunization of
rabbits against a polypeptide (amino acids 1–163). Anti-
bodies were used at the following dilutions: rabbit anti-C.
elegans SART3 (Q5635) 1:2000, mouse anti-Actin (clone
C4, MAB1501, Millipore, Billerica, MA, USA) 1:10 000,
mouse anti-GFP (mixture of clones 7.1 and 13.1, Roche,
Penzberg, Germany) 1:2000, mouse anti-FLAG (clone M2,
F1804, Sigma–Aldrich, St Louis, MO, USA) 1:2000. West-
ern blotting was performed as previously described (38).
Band intensities were quantified using ImageJ software
(NIH, Bethesda, MD, USA).
RNA isolation and northern blotting
Worms were mixed with TRI Reagent (Molecular Research
Center, Cincinnati, OH, USA) and freeze–thawed as de-
scribed previously (39). The RNA was extracted accord-
ing to the manufacturer’s instructions. Total RNA or RNA
from IP’s (see ‘Immunoprecipitation’ section) was sepa-
rated on a 8 M urea–10% polyacrylamide gel electrophore-
sis (PAGE) and transferred to a Hybond-NX membrane
(GEHealthcare, Little Chalfont, UK) by semi-dry blotting.
Cross-linking was carried out byUV irradiation using aUV
Stratalinker 1800 (Stratagene, La Jolla, CA, USA) followed
by baking (1 h at 80◦C). Single-stranded DNA probes were
designed with Unique Probe Selector (http://array.iis.sinica.
edu.tw/ups/index.php). Sequences of probes are given in
Supplementary Table S4. Probes were 5′ end-labeled with
ATP- -[32P] and polynucleotide kinase according to stan-
dard protocols. Hybridization was carried out overnight in
4× SSPE (0.6 M NaCl, 40 mMNaH2PO4, 4 mM ethylene-
diaminetetraacetic acid (EDTA)), 7% sodium dodecyl sul-
fate (SDS), in the presence of 0% to 32% formamide at 37◦C.
Immunoprecipitation
Mixed stage worms (HW1339 or HW1342, see Supplemen-
tary Table S3) were lysedwith aDounce TissueGrinder (BC
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Figure 1. B0035.12 encodes an essential, nuclear protein orthologous to SART3. (A) Schematic representation of the domain structure of Prp24p from
Saccharomyces cerevisiae, SART3 from Homo sapiens, and SART3 from Caenorhabditis elegans. xe3 denotes an N-terminal truncation allele of SART3.
Numbers indicate amino acid positions. HAT = half a TPR, RRM = RNA recognition motif, LID = Lsm interaction domain. (B) Western blot of lysates
extracted from L4 stage worms. Transgenic and endogenous SART3 were detected with an affinity-purified polyclonal antibody against SART3 in lysates
of worms homozygous for the xe3 allele (lane 1), which we obtained by sorting, wild-type worms (lane 2), and xe3 homozygous mutant worms rescued by
transgenic sart-3 containing a C-terminal GFP/His/FLAG-tag (GHF) (lane 3). (C) Differential interference contrast (DIC) micrographs. Adult worms
homozygous for the xe3 allele burst through the vulva (left panel). By contrast, xe3 worms expressing transgenic sart-3::gfp::his::flag (middle panel), like
wild-type worms (right panel), do not burst. Arrows point to the vulva. Scale bar, 20 m. (D) Fluorescence and DIC micrographs of L4 stage worms
expressing C-terminally GFP/3xFLAG-tagged SART3 from a fosmid. Pharynx signal in the head (top left panel) arises from an RFP co-injection marker
leaking into the GFP channel. Arrows point to nucleoplasm, arrow heads point to nucleolus. Scale bar, 20 m. (E) Western blot with lysates from wild-type
worms extracted at different time points during development. L1 = larval stage 1, etc.
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Figure 2. SART3 co-immunoprecipitates U4 and U6 snRNPs. (A) Western blot of anti-FLAG co-immunoprecipitation (co-IP) of N-terminally FLAG-
tagged SART3 (lanes 1–3) and a GFP/His/FLAG control construct (lanes 4–6). Seven percent of input and 15% of IPs were loaded on a gel. (B) Mass
spectrometry results of FLAG/SART3 co-IPs. Numbers of spectra mapping uniquely to a given protein are indicated. IP1: protein extraction using dounce
homogenizer, RNase A treatment performed at room temperature, eluate concentration by TCA precipitation. IP2: protein extraction using mortar and
pestle, RNase A treatment performed at 4◦C, eluate concentration by speed vac. GUT-2 is homologous to human Lsm2 and the SNR proteins to Sm
proteins. The percentage coverage for these proteins is provided in Supplementary Table S1. (C) Northern blot of RNA extracted from eluates obtained by
an anti-FLAG co-IP on lysates from worms expressing the indicated transgene. Two milligram total protein was used as input for the co-IP and 100% of
the co-immunoprecipitated RNA was loaded on the gel. 2.5 g of total RNA were loaded as a reference. Subsets of probes were applied to the membrane
to detect different RNAs simultaneously; the asterisk indicates an unspecific band detected with the probe against U6.
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Scientific, Miami, FL, USA) in 30 mM HEPES/KOH pH
7.4, 100 mM KCl, 1.5 mM MgCl2, 0.1% Triton X-100 and
protease inhibitors (Protease Inhibitor Cocktail Tablets,
EDTA-free, Roche). Lysates were cleared at 16 000 x g for 15
min. RNase A-treated samples were additionally incubated
with 0.1 mg/ml RNase A (Sigma–Aldrich) for 1 h at 4◦C.
For anti-FLAG IP, 2 mg lysate was incubated with anti-
FLAGM2magnetic beads (Sigma–Aldrich) for 2 h.Washes
were performed in lysis buffer. Elution was achieved by in-
cubation with 1 mg/ml FLAG peptide (Sigma–Aldrich).
For RNA extractions, TRI Reagent (Molecular Research
Center) was directly added to themagnetics beads. For anti-
SART3 IP, lysates were incubated with 5 g purified an-
tibody (anti-SART3) for 1 h. Protein A sepharose beads
(Roche) were added for 2 h. Washes were performed in lysis
buffer. Complexes were eluted by heating the beads in sam-
ple loading buffer containing reducing agent for 10 min at
70◦C.
Mass spectrometry
TCA precipitated and acetone washed protein pel-
lets were dissolved in 0.5 M Tris–HCl pH 8.6, 6 M
guanidinium hydrochloride, reduced in 16 mM tris(2-
carboxyethyl)phosphine (TCEP) for 30 min, and alkylated
in 35 mM iodoacetamide for 30 min in the dark. The
proteins were digested at 37◦C with trypsin (Promega,
Madison, USA) after 6× dilution in 50 mM Tris–HCl
pH 7.4, 5 mM CaCl2 overnight. The resulting peptides
were separated on a 75 m × 10 cm Magic C18 column
(Michrom, Bioresources, Auburn, USA) with an Agilent
1100 Nanoflow LC System (Agilent, Palo Alto, CA, USA).
The LC was connected to a LTQ Orbitrap Velos (Thermo
Scientific). Mascot (Matrix Science, London, UK) search-
ing UniProt data base version 2012 09 was used to identify
the peptides.
Microscopy
DIC and fluorescent images were obtained using an Axio
Observer Z1 microscope and AxioVision SE64 (release 4.8)
software (Carl Zeiss, Oberkochen, Germany). Stereoscopic
images were obtained by a M205 A stereo microscope (Le-
ica, Solms, Germany).
MosDEL
The xe3 allele was obtained by following the protocol es-
tablished by (40). A targeting plasmid was created using the
Multisite Gateway Technology (Life Technologies). Spe-
cific primers (Supplementary Table S4) were used to am-
plify the left (2039 bp) and right (2988 bp) homology
regions from genomic DNA and amplicons were cloned
into pDONRP4-P1R and pDONRP2R-P3, respectively.
Together with pENTR221 containing and unc-119 res-
cue gene a pDESTR4-R3 targeting plasmid was created.
The targeting plasmid was injected at 50 ng/ul into strain
HW1350, aMos1-engineered strain (IE5820 containing the
ttTi5820 allele) obtained from the NemaGENETAG con-
sortium (41) which we crossed into an unc-119(ed3)mutant
background. Following injection, wild-type moving worms
were screened for successful integration of the transgene by
PCR (Supplementary Table S4 for primer sequences). The
isolated deletion allele was balanced with nT1[qls51] and
the resulting strain was calledHW1337 (Supplementary Ta-
ble S3).
Recombinant protein expression and purification
cDNA for ZK863.4/USIP-1, either wild-type or contain-
ing the point mutations D183A and D185A (USIP-1cd),
was cloned into pOPINE (introducing a C-terminal hexa-
histidine tag). USIP-1/USIP-1cd was transformed into Es-
cherichia coli BL21 cells. A starter culture (GS96 medium
supplemented with 0.05% glycerol, 1% glucose, 50 g/ml
carbenicillin) was inoculated and incubated for 11 h at 37◦C
and 225 rpm. An expression culture (ZYP-5052 medium
for auto-induction) was inoculated with the starter culture
(1:100) and incubated for 4 h at 37◦C followed by 20 h at
20◦C. Cells were harvested by spinning for 30 min at 6500 x
g at 4◦C. The pellet was resuspended in wash buffer (20 mM
NaH2PO4, 500 mM NaCl, 20 mM imidazole, pH 7.5) con-
taining 0.5% Tween (v/w). The suspension was sonicated
in the presence of Benzonase (3 U/ml culture) and protease
inhibitors (Protease Inhibitor Cocktail Tablets, EDTA-free,
Roche). The lysate was cleared by spinning for 30 min at
30 000 x g at 4◦C. USIP-1/USIP-1cd was purified from
the cleared lysate using a HisTrap HP column (5 ml) (GE
Healthcare) on an A¨KTApurifier 10 HPLC (GE Health-
care). Recombinant protein was recovered from the column
with elution buffer (20 mM NaH2PO4, 500 mM NaCl, 500
mM imidazole, pH 7.5), concentrated with Amicon Ultra-4
centrifugal filter units (10 000 K, Millipore) and stored at
−20◦C in 10 mM Tris–HCl pH 7.5, 100 mM NaCl, 1 mM
Dithiothreitol (DTT), 50% glycerol.
Transferase assay
Twenty micrograms recombinant USIP1 or USIP-1cd were
added to 200 ng of a synthetic RNA 22mer (AGCCGCAU-
UUCGUAGUGAUAUU) in the presence of 1 mM UTP
(or, when appropriate, ATP, CTP or GTP), RNasin (40
U/l) (Promega, Madison, USA), and reaction buffer (10
mM Tris–HCl pH 7.5, 50 mM NaCl, 10 mM MgCl2, 1
mM DTT) in a total volume of 15 l. Samples were incu-
bated at 25◦C for 0–10 min and the reaction was stopped by
adding 950 l TRI Reagent (Molecular Research Center).
The RNA was extracted according to the manufacturer’s
instructions and the reaction products were separated by 8
M urea–15% PAGE. The RNA was visualized by incubat-
ing with SYBR Gold. In Figure 4D, 30 ng gel-purified U6
RNA was incubated with recombinant protein in the pres-
ence of 1.6 M UTP--[32P] (800 Ci/mmol) mixed with
200 Mcold UTP for 5 min at 25◦C. The reaction products
were separated by 8 M urea–10% PAGE and visualized by
autoradiography. In vitro transcribed U6 was obtained us-
ing the MEGAscript Kit (Life Technologies) on synthetic
double-stranded DNA corresponding to the U6 sequence
with five deoxythymidines at the 3′ end and including the
T7 promoter at the 5′ end. Note that the T7 promoter intro-
duces three artificial guanosine residues at the 5′ end during
transcription.
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3′ RACE
To determine the 3′-terminal sequence of U6 snRNA, we
ligated the 3′ RNA adapter from the TruSeq Small RNA
Sample Preparation Kit (Illumina, San Diego, CA, USA)
onto 1 g total RNA according to the supplier’s protocol.
Ligated RNA was reverse transcribed for 30 min at 42◦C
followed by 1 h at 50◦C using a primer that introduces a
primer binding site for subsequent amplification (Supple-
mentary Table S4) and components of the TruSeq Small
RNA Sample Preparation Kit (Illumina).The reverse tran-
scriptase was inactivated by incubation of the sample at
70◦C for 15 min. The cDNA was diluted 1:10 and U6 was
amplified using a U6-specific primer and a primer com-
plementary to the region introduced by reverse transcrip-
tion (Supplementary Table S4) by Taq DNA polymerase
(New England Biolabs, Ipswich, MA, USA). PCR ampli-
cons were cloned into the pCR4TOPO vector according to
the supplier’s protocol (Life Technologies) and sequenced.
RESULTS
sart-3 is a ubiquitously and constitutively expressed gene re-
quired for C. elegans viability
Although U6 snRNP recycling is arguably the best under-
stood function of SART3, this protein has also been im-
plicated in other pathways, including, by virtue of its in-
teraction with the human AGO1 and AGO2 proteins, in
small RNA silencing (15). To gain further insight into the
physiological functions of SART3, we studied theC. elegans
protein B0035.12. Although the overall sequence identity
with the human protein is low (26%), the domain compo-
sition is highly conserved (Figure 1A) and includes several
HAT (half a TPR) repeats in theN-terminal part, twoRNA
recognition motifs (RRMs) in the C-terminal part, and an
Lsm interaction domain (LID) at the C-terminus. For this
and other reasons that we will describe below, we named the
B0035.12 gene sart-3, encoding the SART3 protein.
We used the MosDEL technique for targeted gene dis-
ruption (40) to delete amino acids 1–715 of the endogenous
sart-3 locus, generating the sart-3(xe3) mutant allele (Fig-
ure 1A). An affinity-purified polyclonal antibody against
SART3 failed to detect a band for full-length SART3 in a
Western blot with lysates from L4 stage worms homozy-
gous for the xe3 allele (Figure 1B, compare lanes 1 and
2), which we obtained through fluorescence-based sorting
of the progeny of sart-3(xe3)/nT1[qls51] animals carrying
a GFP-marked balancer (see ‘Materials and Methods’ sec-
tion for details). As the antibody was generated against an
N-terminal polypeptide (amino acids (aa) 1–166), the ac-
cumulation of a C-terminal fragment (aa 716–836) remains
hypothetically possible, but seems unlikely given the lack of
an ATG start codon in the corresponding DNA sequence.
Homozygously sart-3(xe3) mutant animals died as
young adults from vulval rupturing with a penetrance of
100% (n= 20) (Figure 1C, left panel). Expression of a single-
copy integrated transgene encoding SART3 C-terminally
fused to a GFP/His/FLAG triple tag (GHF) and expressed
from a ubiquitous dpy-30 promoter (Pdpy-30::sart-3::ghf)
restored the wild-type situation (Figure 1C, middle and
right panels). Western blot analysis verified that the levels
of the SART3/GHF and endogenous SART3 are compara-
ble (Figure 1B, compare lanes 2 and 3). Hence, we conclude
that lethality is a consequence of sart-3mutation, revealing
that sart-3 is essential for C. elegans development and via-
bility.
Visual inspection of dpy-30::sart-3::ghf animals indi-
cated nuclear steady-state localization of the tagged protein.
However, it was possible that intracellular localization was
influenced by the use of the heterologous dpy-30 promoter,
which we had used because sart-3 is the second gene in a
three-gene operon (Wormbase WS244; (42)). Therefore, to
confirm this localization and examine spatial and temporal
expression patterns of sart-3, we generated a distinct trans-
genic strain that produced SART3/GFP/3xFLAG from a
fosmid (33), and thus under endogenous cis regulatory con-
trol (Figure 1D).Whereas mammalian SART3 accumulates
strongly in nuclear foci termed Cajal/Coiled Bodies (CBs)
(43,44), we observed diffuse nucleoplasmic staining for C.
elegans SART3 (Figure 1D). This finding is consistent with
the fact that the C. elegans genome lacks an obvious ortho-
logue of coilin (Wormbase WS244; (42)), a key structural
component of CBs (45).
The transgene also revealed widespread, presumably
ubiquitous, and constitutive accumulation of SART3. To
confirm the latter, we examined endogenous SART3 lev-
els at different time points during development by west-
ern blot, which revealed sustained sart-3 expression (Fig-
ure 1E). Taken together, SART3 is a constitutively and ubiq-
uitously expressed nuclear protein that is essential for C. el-
egans vulval integrity and thus viability.
C. elegans SART3 associates with the U4/U6 snRNP
Although vulval bursting may occur through dysregula-
tion of diverse pathways, it is also a hallmark of miRNA
dysfunction in C. elegans (46,47), possibly supporting
a notion of SART3 functioning in this pathway (15).
Whereas nuclear steady-state localization argued against
a function in cytoplasmic Argonaute complexes, a role
in miRNA biogenesis remained possible. Hence, to un-
derstand the key pathways of SART3 function in C. el-
egans, we precipitated functional, N-terminally FLAG-
tagged SART3 (FLAG/SART3) or as a negative control a
GFP/His/FLAG triple tag from mixed stage worm lysates
using an anti-FLAG antibody (Figure 2A). Precipitates
were eluted by incubation with FLAG peptide and exam-
ined bymass spectrometry.Wewere unable to identify inter-
action with any known miRNA pathway components. By
contrast, we detected a full complement of Lsm2 (GUT-2
in C. elegans) through Lsm8 proteins (Figure 2B and Sup-
plementary Table S1), which make up the protein core of
the U6 snRNP (2). We did not observe Lsm1, which forms
a related complex on mRNAs destined for degradation but
absent from the U6 snRNP (2). To confirm that SART3
bound to the entire U6 snRNP, we performed northern blot
analysis of RNA co-immunoprecipitated with this protein,
and observed a strong enrichment of U6 snRNA relative to
tRNAGly (Figure 2C).
In addition to Lsm proteins, FLAG/SART3 also im-
munoprecipitated the Sm proteins that form the protein
core of the U1, U2, U4 and U5 snRNAs, with only SNR-
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Figure 3. SART3 and USIP1/ZK863.4 are in a U6 snRNA-containing complex. (A) Western blot of anti-FLAG co-IP of C-terminally GFP/3xFLAG-
tagged USIP-1 (lanes 1 and 3–5) and a C-terminally His/FLAG-tagged GFP control construct (lanes 2 and 6–8). USIP-1/GFP/3xFLAG and
GFP/His/FLAG constructs were detected with anti-GFP. Endogenous SART3 was detected with a polyclonal antibody against SART3. Two percent
of input and 70% of IPs were loaded on a gel. (B) Proteins identified by mass spectrometry following IP of FLAG-tagged SART3, USIP-1 or GFP. The
latter serves as a negative control (see additional proteins in Supplementary Table S2). Numbers of spectra mapping uniquely to a given protein are indi-
cated. (C) Northern blot of RNA extracted from eluates obtained by an anti-FLAG co-IP on lysates from worms expressing the indicated transgene. Two
milligram total protein was used as input for the co-IP and 100% of the co-immunoprecipitated RNA was loaded on the gel. 2.5 g of total RNA were
loaded as a reference. Subsets of probes were applied to the membrane to detect different RNAs simultaneously; the asterisk indicates an unspecific band
detected with the probe against U6. (D) Fluorescence and DIC microscopy of L4 stage worms expressing C-terminally GFP/3xFLAG-tagged USIP-1
from a fosmid. Arrows point to nucleoplasm, arrow heads point to nucleolus. Scale bar, 20 m.
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Figure 4. USIP-1 is a terminal uridylyl transferase. (A) Schematic representation of the domain structure of STPAP/RBM21/TUT1 (UniProt:
STPAP HUMAN) and MTPAP/PAPD1 (PAPD1 HUMAN) from H. sapiens, and the C. elegans proteins GLD-4 (GLD4 CAEEL) and USIP-1
(Q23652 CAEEL). tm1897 denotes a deletion allele of USIP-1 that leads to a frame shift (striated) and premature termination codon at position 276.
C2H2 ZF = C2H2-type (classical) zinc finger (ZF), RRM = RNA recognition motif, PAD = PAP-associated domain, DXD: Amino acid motif required
for catalytic activity where D = aspartic acid and X = any amino acid. (B) Assay to test terminal transferase activity of recombinant USIP-1 and USIP-
1cd. Twenty micrograms of recombinant protein was added to 200 ng of a synthetic 22-nucleotide-long RNA substrate in the presence of 1 mMUTP. The
reaction was stopped by addition of Trizol between 0 and 10 min. Shown is a SYBRGold staining of a 15% urea–polyacrylamide gel (inverted picture). M
=Marker. (C) Transferase assay similar to (B) with different nucleotide triphosphates. (D) Autoradiography of transferase activity of recombinant USIP-1
or USIP-1cd on gel-purified U6 RNA from the indicated sources using radioactively labeled UTP--[32]P.
6/Sm E being undetectable (Figure 2B). We thus tested
whether FLAG/SART3 also interacted with additional U
snRNAs. We found that SART3 did not appreciably bind
U1, U2 or U5 snRNAs (Figure 2C). However, it efficiently
co-immunoprecipitated U4 snRNA (Figure 2C), suggest-
ing that the binding to the Sm proteins could be mediated
through U4. Consistent with this notion, RNase A treat-
ment of lysates prevented co-immunoprecipitation of both
Lsmand SmproteinswithFLAG/SART3 (Figure 2B). Col-
lectively, these data are consistent with the notion thatC. el-
egans SART3, like its mammalian and yeast counterparts,
functions in recycling of post-splicing U6 snRNP by rean-
nealing U4 and U6 snRNAs to generate a di-snRNP.
ZK863.4/USIP-1 is in a complex with SART3 and U6
snRNA
In addition to Lsm and Sm proteins, FLAG/SART3
reproducibly co-immunoprecipitated a novel protein,
ZK863.4/USIP-1 (Figure 2A). We verified that, recipro-
cally, ZK863.4/USIP-1 tagged with GFP/3xFLAG (33),
expressed from a multicopy fosmid transgene array, was
capable of co-immunoprecipitating SART3 (Figure 3A and
B). As the interaction of ZK863.4/USIP-1 and SART3 was
sensitive to RNase A treatment (Figure 3A), we wondered
if it was mediated by U6 and/or U4 snRNAs. Indeed,
analysis of co-precipitating RNA by Northern blotting
revealed the presence of U6 snRNA (Figure 3C), leading us
to term this protein USIP-1 for U-Six snRNA Interacting
Protein. However, U4 snRNA was not co-precipitated
(Figure 3C), and Sm proteins were not enriched above the
background of a GFP/His/Flag control immunoprecipita-
tion (Figure 3B). Hence, unlike SART3, USIP-1 does not
appear to occur on the U4/U6 di-snRNP. In fact, as Lsm
proteins did not detectably co-immunoprecipitate with
USIP-1 either, it appears that USIP-1 binds preferentially
to U6 snRNA that is not assembled into the canonical
U6 snRNP. Additional proteins co-immunoprecipitated
with SART3 and USIP-1 but are not further pursued in
this study (Supplementary Table S2). Similar to SART3,
we found the USIP-1/GFP/3xFLAG multicopy array to
be expressed diffusely throughout the nucleoplasm but
depleted from the nucleolus and expressed constitutively
and ubiquitously across different tissues (Figure 3D).
USIP-1 is a terminal nucleotidyl transferase
Sequence analysis of USIP-1 suggested that it was a ribonu-
cleotidyl transferase, as it contained both the DXD mo-
tif and PAD domain characteristic of this class of enzymes
(48) (Figure 4A). To determine whether USIP-1 was a func-
tional enzyme, we produced recombinant wild-type protein
through expression in E. coli (Supplementary Figure S1).
Additionally, we produced a variant containing a double D-
>Amutation in the DXDmotif, USIP-1 (D183A, D185A),
which is expected to abrogate Mg2+ binding and thus en-
zymatic activity (48,49). We will refer to the catalytic-dead
protein asUSIP-1cd in the following. Incubation of thewild-
3352 Nucleic Acids Research, 2015, Vol. 43, No. 6
type enzymewith a synthetic RNAoligonucleotide revealed
distributive ribonucleotidyl transferase activity as shown by
extension of the substrate (Figure 4B). This activity de-
pended on the recombinant wild-type protein as USIP-1cd
was inactive (Figure 4B). Moreover, examination of the ac-
tivity with different nucleotide triphosphates revealed activ-
ity preferentially in the presence of UTP (Figure 4C). In
conclusion, USIP-1 is a bona fide terminal uridylyl trans-
ferase (TUTase).
USIP-1 can extend endogenous U6 snRNA
The 3′ end of mature U6 snRNA is usually chemically mod-
ified in a manner that renders it resistant to periodate-
induced shortening through beta-elimination (50). In C.
elegans, a vast majority of U6 snRNA molecules is
‘blocked’ at its 3′ end in this manner, but the identity
of the relevant modification is not known (50). To exam-
ine whether endogenous U6 snRNA was a suitable sub-
strate of USIP-1, we gel-purified this RNA from USIP-
1 and SART3 co-immunoprecipitates, respectively. When
equimolar amounts of USIP-1- or SART3-bound U6
snRNA, or in vitro-transcribed U6 snRNA were incu-
bated with USIP-1 and radiolabeled -[32]P-UTP, label-
ing occurred on all three RNAs and was similar in ex-
tent (Figure 4D). By contrast, no labeling occurred when
USIP-1cd was used. We conclude that USIP-1 is capa-
ble of extending endogenous U6 snRNA. Moreover, 3′-
monophosphorylated synthetic RNAwas refractory to tail-
ing by USIP-1 (Supplementary Figure S3), consistent with
the finding that the U6 snRNA of C. elegans, unlike that
of other organisms, does not carry a 2′,3′-cyclo- or 3′-
monophosphate blocking group (50). Interestingly, another
common RNA modification, 2′-O-methylation, similarly
abrogated USIP-1-mediated tailing (Supplementary Figure
S3), suggesting the presence of amore unusual modification
on the U6 snRNA 3′ end, which remains to be identified.
SART3 depletion is synthetically lethal with loss of USIP-1
TUTase activity
Genetic modulation, i.e. enhancement or suppression of
mutant phenotypes, is an established way to identify genes
functioning in shared or parallel pathways. Hence, we
sought to use modulation of usip-1 and sart-3 mutant phe-
notypes to confirm that both these genes function in U6
snRNA pathways. In order to look for genetic interac-
tion, we made use of a partial deletion mutant of usip-1,
usip-1(tm1897), kindly provided by Dr Shohei Mitani. The
tm1897 allele is a deletion of 542 bases that leads to a frame
shift at amino acid position 233 (I233T) and to a premature
termination codon shortly after (S276Stop), suggesting it to
be a hypomorph or null mutation (Figure 4A).
usip-1(tm1897) mutant animals were viable and overtly
fine. Extensive depletion of SART3 by RNAi (Supplemen-
tary Figure S2), unlike its complete deletion, failed to yield
overt phenotypes beyond a moderately reduced brood size
when scored after 60 h at 25◦C (Figure 5A). However, when
usip-1(tm1897) mutant animals were additionally treated
with sart-3(RNAi), embryonic lethality ensued (Figure 5A
and B). In order to exclude the possibility that the un-
hatched embryos were just developmentally delayed and
would hatch at a later time point, we assessed them after 96
h at 25◦C and found them still arrested (Figure 5B). Closer
inspection revealed that the embryos arrested at various de-
velopmental stages (data not shown). The few worms that
did hatch under usip-1(tm1897); sart-3(RNAi) conditions
arrested at the L1 stage (Figure 5B). Hence, these data are
consistent with the notion that USIP-1, like SART3, is im-
portant for U6 snRNA function.
The genetic interaction permitted us to test the relevance
of the TUTase activity of USIP-1 for its in vivo function.
To do so, we expressed transgenes that encoded wild-type
USIP-1 or USIP-1cd, respectively, in usip-1(tm1897) mu-
tant animals, which we then exposed to RNAi against sart-
3. Strikingly, although USIP-1 and USIP-1cd accumulated
to similar levels (Figure 5C), only the wild-type protein
supported viability (Figure 5A). Hence, TUTase activity
of USIP-1 appears essential when SART3 activity is de-
creased.
Loss of USIP-1 leads to U6 snRNA destabilization
With genetic and biochemical evidence thus strongly im-
plicating USIP-1 in U6 snRNA function, we sought to de-
termine whether USIP-1 affected U6 snRNA levels. Using
Northern blotting, we observed decreased U6 snRNA lev-
els in usip-1(tm1897) mutant relative to wild-type animals
(Figure 6A and Supplementary Figure S4). The defect inU6
snRNA accumulation was partially rescued by transgene-
directed expression of USIP-1 but not USIP-1cd (Figure 6A
andB). Similar findings weremadewhenU6 snRNAbound
to SART3 was examined (Figure 6C). Moreover, although
U4 snRNA levels in total lysates remained unaffected by
loss of USIP-1 or its catalytic activity, its abundance in
SART3 co-IPs was reproducibly reduced when USIP-1 was
absent (Figure 6C). We conclude that USIP-1 and its TU-
Tase activity are required for U6 snRNA accumulation and
that defective U6 snRNA accumulation may be a cause of
the synthetic lethality that occurs in usip-1(tm1897); sart-
3(RNAi) animals.
Although no obvious differences inU6 snRNAmigration
occurred in RNA from usip-1(tm1897) relative to wild-type
animals (Figure 6A), minor differences in the oligo-U tail
length of this RNA might not be detected at the resolution
of our gel system. Hence, we performed rapid amplification
of cDNA ends (RACE) analysis and examined U6 snRNA
3′ ends by sequencing. In wild-type animals, mostmolecules
contained an oligo-U tail of four to six nucleotides; with
few examples of shorter tails (Figure 6D). This is consistent
with a stretch of four to six T’s serving as the termination
sequence of RNApolymerase III, and the preferential bind-
ing of Lsmproteins toU4 tails. Surprisingly, this patternwas
unaltered in usip-1 mutants (Figure 6D). This finding sug-
gests that U6 snRNAmolecules that cannot be extended to
their normal length of≥4 U nucleotides at the 3′ end due to
loss of USIP-1 are rapidly degraded.
DISCUSSION
Whereas the splicing process and mechanisms of spliceo-
some activation are understood in substantial detail, much
less is known about processes that promote reutilization of
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Figure 5. Synthetic embryonic lethality occurs when simultaneously compromising SART3 and USIP-1 activity. (A) Wild-type worms or worms homozy-
gous for the tm1897 allele were exposed to mock or sart-3RNAi at the L1 stage (P0 generation) and cultured at 25◦C. After 60 h, the hatched progeny (F1
generation) was counted. n= 3, error bars indicate SEM. (B) Wild-type worms or worms homozygous for the tm1897 allele were exposed to mock or sart-3
RNAi at the L1 stage (P0 generation) and cultured at 25◦C. Pictures of the next generation (F1 generation) were taken after 96 h revealing hatched F1’s
(that were arrested due to lack of food though) for wild-type; mock RNAi, wild-type; sart-3RNAi and usip-1(tm1897);mock RNAi but arrested embryos
or L1 stage worms (arrow) for usip-1(tm1897); sart-3 RNAi. (C) Western blotting shows similar protein levels for transgenic, FLAG-tagged wild-type
USIP-1 or mutant USIP-1cd. Both transgenes are expressed in a usip-1(tm1897) background and were detected by an anti-FLAG antibody.
the spliceosome for additional rounds of splicing (1). We
propose here that USIP-1 is a novel U6 snRNA recycling
factor.We note that at this point we cannot formally exclude
a role ofUSIP-1 inU6 snRNAbiogenesis. However, the fact
that USIP-1 interacts both physically and genetically with a
bona fide U6 snRNA recycling factor strongly implies that
U6 snRNA recycling is amajor function ofUSIP-1. Indeed,
when integrating the results that we present in the current
study with previous data onU4/U6 di-snRNP regeneration
(5,8,9,51), a U6 snRNA recycling pathway begins to emerge
(Figure 7). In particular, we propose that USIP-1 binds to
‘post-spliceosomal’ U6 snRNA, devoid of Lsm proteins.
Subsequently or coincidentally, SART3 is recruited to this
complex. The complex then matures to acquire Lsm pro-
teins as well as the U4 snRNP (24,27,29), associated with
Sm proteins, while ejecting USIP-1.
This model is supported as follows: In vitro studies pre-
viously suggested the possibility that Lsm proteins disso-
ciate from the U6 snRNP during spliceosome activitation
(52,53), thus generating the presumed USIP-1 substrate.
Moreover, because Lsm proteins bind to the very 3′ termi-
nus of U6 snRNA (26) to which a TUTase also needs to
bind to extend the RNA, we can anticipate that binding
of TUTase and Lsm proteins is mutually incompatible. Fi-
nally, SART3 occurs in two distinct complexes that contain
either only U6 snRNA or both U4 and U6 snRNA (8), pre-
3354 Nucleic Acids Research, 2015, Vol. 43, No. 6
0
0.2
0.4
0.6
0.8
1
1.2
0
5
10
15
20
25
30
35
1 2 3 4 5 6 7
U6
U4
1.0 0.4
1.0 0.7
us
ip-
1(+
); fl
ag
::s
ar
t-3
α-FLAG IP
1.0
1.0
0.4
0.8
us
ip-
1(+
); fl
ag
::s
ar
t-3
α-FLAG IP
Repl1 Repl2
A
B
C
U4
U6
U1
us
ip-
1
us
ip-
1
cd
  background
transgene
tm1897N2
- -
wi
ld-
typ
e
U6/U1
us
ip-
1(t
m1
89
7)
us
ip-
1(t
m1
89
7);
 us
ip-
1
cd
fo
ld
 c
ha
ng
e
U4/U1
D
fr
ac
tio
n 
of
 to
ta
l [
%
]
length of U tail  [nt]
wild-type (n=28)
usip-1(tm1897) (n=29)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
*
wi
ld-
typ
e
us
ip-
1(t
m1
89
7)
us
ip-
1(t
m1
89
7);
 us
ip-
1
cd
fo
ld
 c
ha
ng
e
*
n.s.
n.s.n.s.
n.s.
Figure 6. USIP-1 stabilizes U6 snRNA. (A) Northern blot with RNA extracted from wild-type worms (N2) or usip-1(tm1897) worms. The latter contain
either no transgene or transgenic usip-1 or usip-1cd. (B) Quantification of northern blots as shown in (A) from experiments with four biological replicates,
mean + SEM. *P-value < 0.05 by a paired two-tailed t-test; n.s., not statistically significant. (C) Northern blot with RNA isolated from immunoprecip-
itated FLAG/SART3. FLAG/SART3 was immunoprecipitated from wild-type worms (usip-1(+)) or usip-1(tm1897) worms. Two replicates are shown.
Quantification of bands is relative to the underlined value, which has been set to 1. (D) 3′ end sequences of U6 snRNA from wild-type and usip-1(tm1897)
worms were determined by 3′ RACE analysis and grouped as indicated according to length of the oligo-U tail. [Note that only tail sequences consisting
entirely of Us were used for the analysis depicted here, but that comparable results were obtained when including the occasional tail sequences that contain
As in addition to Us (data not shown).]
Nucleic Acids Research, 2015, Vol. 43, No. 6 3355
UUU(n)
UUUUU
UUUUU
Figure 7. Model of the life cycle of U6 snRNA. Additional snRNP-
associated proteins (1) are omitted for the sake of simplicity. See text for
details.
sumably corresponding to early and late steps ofU6 snRNA
recycling.
It was previously suggested that Lsm proteins facilitated
recruitment of SART3 to the U6 snRNA because in vitro
their strong binding to this snRNA stabilized the weak
binding of SART3 to U6 (28). However, these experimen-
tal data are equally consistent with a model where bind-
ing of SART3 to U6 can initiate in the absence of Lsm
proteins, possibly facilitated by USIP-1 binding to the U6
snRNA, but then gaining stability, and possibly specificity
(7), through interaction with the Lsm toroid. At any rate,
the presence of both SART3 and Lsm proteins may then
maintain the U6 snRNA, now devoid of USIP-1, in a
configuration that promotes annealing to the U4 snRNA
(24,27,29).
The destabilization of U6 snRNA upon loss of USIP-1
might be explained by the fact that binding of the Lsm com-
plex to U6 snRNA requires the latter’s 3′-terminal oligo-U
tail (24–26). Failure to reconstitute the U6 snRNA oligo-U
tail to its normal length of four to five nucleotides will thus
impair binding of the Lsm complex. This, in turn, might
make the U6 snRNAmore susceptible to nucleolytic decay,
in particular through an exonucleolytic attack on its now
freely accessible 3′ end. Although not proof, the fact that
trimmed U6 snRNA molecules fail to accumulate in usip-
1 mutant animals is indeed consistent with their being an
unstable RNA species.
Although no direct one-to-one orthologue of USIP-
1 can be identified in mammalian cells, it appears
most similar to mitochondrial poly(A) RNA polymerase
(MTPAP/PAPD1) (54) and speckle targeted PIP5K1A-
regulated poly(A) polymerase (STPAP/RBM21/TUT1)
(55) (Figure 4A). Interestingly, STPAP was originally iden-
tified by virtue of its biochemical activity, the specific ad-
dition of uridine nucleotides to U6 snRNA, and named
U6 TUTase (56,57). However, its physiological function
remained unknown, and was further obscured by subse-
quent work suggesting that a select set of mRNAs, not U6
snRNA, were its substrates, which it preferentially extended
with adenosine, not uridine (55). Althoughwe do not under-
stand the basis of these inconsistent findings, we note that
siRNA-mediated depletion of STPAP was recently shown
to decrease the length heterogeneity of cellular U6 snRNA
in HeLa cells (58) suggesting that U6 snRNAmight indeed
be one of its cellular substrates. Hence, we speculate that
STPAP/U6 TUTase function analogously to USIP-1. The
divergence in sequence, functions, and domain organization
between USIP-1 and STPAP may then reflect peculiarities
inU6 snRNA3′ end formation pathways among eukaryotes
(50,59).
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